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Abstract: There is signiﬁ  cant evidence supporting an increased prevalence of depression in 
patients with COPD, but that depression is not a homogenous entity because there are multiple 
contributing etiologies for the depressive symptoms. Additionally the relationship between COPD 
and depression is neither exclusively linear, nor unidirectional. “Early onset” depression is deﬁ  ned 
as depression that develops prior to the diagnosis of COPD, often during an individual’s youth. 
This is often reﬂ  ective of a genetic vulnerability to depression which increases adolescents’ risk 
for developing addiction to nicotine, setting up a life-long exposure to tobacco – the single greatest 
risk factor for the development of COPD. When COPD does develop it brings with it attendant 
losses, particularly in level of independent function and self image that contribute to a “reactive” 
depression that is not distinct from the losses experienced by those suffering with other chronic 
illnesses. Lastly there is increasing evidence through magnetic resonance imaging (MRI) and bio-
chemical markers that systemic, physiologic changes associated with COPD have direct effects on 
the brain’s vasculature that have also been associated with depression in the elderly, termed “late 
onset” depression. The conclusion is that the presence of depression in a COPD patient does not 
reﬂ  ect a single pathologic pathway. Rather the two disorders each contribute to the morbidity of 
the other. This review discusses the evidence supporting each of these contributors and suggests 
that an understanding of these varying elements can direct healthcare interventions.
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Introduction
A review of epidemiologic studies demonstrates a prevalence of co-morbid depression 
in a range of 6%–80% of COPD patients, with an average among the majority of the 
strongest studies of approximately 40%. This compares to a rate of 15% in the general 
population (Light et al 1985; van Ede et al 1999; Yohannes 2000; Aydin and Ulusahin 
2001; Kunik et al 2005). In cardiac patients the range is 15%–23% (Carney et al 1997; 
Ariyo et al 2000; Ziegelstein 2001) and in cancer patients over a range of 13%–38% 
(Kathol et al 1990). In a cluster of studies that have compared depressive disorders 
across diverse chronic illnesses, COPD patients suffer from depression with greater 
frequency and a greater chronicity of the mood symptoms (Kurosawa 1983; Katon and 
Sullivan 1990; Evans et al 1999; Cruess et al 2003). Evidence suggests, however, that 
the depression experienced by COPD patients is not a homogenous entity. To manage 
this co-morbidity as effectively as possible it is important to ﬁ  rst understand the poten-
tial contributors to an individual patient’s depression. Chronologically the earliest risk 
may be a genetic predisposition to depression, followed by the environmental assaults 
imposed by the respiratory illness itself and ﬁ  nally the direct neuropsychiatric effects 
of chronic respiratory disease. The goal of this review is to explore each of these ele-
ments to help inform clinical management of this patient population.
Genetics
In the psychiatric literature the heritability of a vulnerability to depression has been 
well established. First-degree relatives of individuals with major depression are 2 to International Journal of COPD 2007:2(4) 486
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3 times as likely to develop depression when compared to 
the ﬁ  rst-degree relatives of controls. This increased risk is 
also supported by adoption and twin studies. The latter show 
a concordance rate of 50% in monozygotic twins, 10%–25% 
in dizygotic (Kaplan and Sadock 1988; Sullivan et al 2000; 
Kendler et al 2006). The age at which this increased risk 
manifests varies widely from individual to individual, but 
is often already evident in adolescence (Elely et al 2004). 
This vulnerability plays a role in the eventual development 
of COPD in that adolescents and young adults who are 
depressed or have a history of depression are more likely to 
progress in their use of and dependence on nicotine (Breslau 
et al 1993; Ferguson 1996; Patton et al 1996). The genetic 
underpinning of this vulnerability has recently gained 
increased support with the ﬁ  nding that the likelihood of 
an adolescent’s smoking progressing from initial nicotine 
exposure to regular smoking was doubled by each additional 
copy of an identiﬁ  ed allele (DRD2A1) for a subtype of a 
dopamine receptor. The presence of depressive symptoms 
magniﬁ  ed the effect (Audrain-McGovern et al 2004). These 
data would suggest that smoking interventions that have 
been implemented in adults – such as the administration of 
antidepressants – might also be useful to help adolescents 
stop smoking, but there is currently very limited evidence 
for any effective interventions in this population. Certainly 
this is an area that warrants further research.
Smoking, COPD and depression are interrelated in a sort 
of trinity, with depression playing a role in the initiation and 
maintenance of smoking, smoking leading to the develop-
ment of COPD and COPD, in turn, contributing to the genesis 
of depression. Because of depression’s role in the develop-
ment of nicotine dependence, it might also be considered a 
risk factor for COPD. In adults, continued smoking increases 
the morbidity and mortality experienced in COPD. A history 
of either recent or distant depression has been associated with 
diminished success in smoking cessation, more persistent 
withdrawal symptoms and an increased likelihood of recur-
rence of the depression if nicotine is discontinued (Covey et al 
1997, 1998; Covey 1999). The application of antidepressant 
therapy in smokers who endorsed some level of depressive 
symptoms did increase abstinence rates up to three months 
out from quit dates (Hitsman et al 1999), a ﬁ  nding consis-
tent with previous reports (Hurt et al 1997; Hall et al 1998; 
Niaura et al 2001). There is suggestion that the beneﬁ  ts from 
the application of antidepressants is not exclusively due 
to the relief of depressive symptoms but potentially because 
the vulnerability to nicotine dependence and to depression 
share a common genetic source, possibly one that deﬁ  nes 
some characteristic of the dopamine pathways (Lerman and 
Berrettini 2003).
The impact of chronic illness
The responses to the question of why depression arises so 
frequently in COPD reﬂ  ect an evolving understanding of the 
complex relationships between these two disease entities. 
Early theory held that depression in chronic illness was a 
“reaction” to the losses imposed by the illness – an understand-
able grieving (Agle and Baum 1977). Since that time both 
the reactions and the losses have been more clearly deﬁ  ned. 
Loss of functionality is a strong mediator of the development 
of depression in chronic illness, with an attributable risk 
measured at 34% (Dunlop et al 2004). Functional impacts 
may include decreased mobility, inability to carry out prior 
occupational activities, shifted roles within the family constel-
lation and decreased ability to physically participate in previ-
ously enjoyed recreational activities. Another common insult 
to self-image that COPD patients struggle with is the use of 
supplemental oxygen. In fact, this insult often contributes to 
patients’ reluctance to utilize oxygen therapy (Earnest 2002). 
The psychological losses attached to each of these insults are 
ﬁ  rst the loss of the phenomenon itself and secondly of the 
emotional or material beneﬁ  ts derived from it.
A second factor in a patient’s ability to adjust to the bur-
den of illness is the patency of internal coping mechanisms 
including self-efﬁ  cacy and sense of mastery. The stronger 
patients’ sense of mastery or ability to impact the daily 
experience of their illness, the lower is their risk for depres-
sion (Brown 1986, Holahan and Holahan 1987). In a cohort 
of 208 severe COPD patients their level of perceived self-
efﬁ  cacy and functionality had a greater impact on variability 
in perceived quality of life than either objective or subjective 
pulmonary function (Kohler et al 2002).
A third inﬂ  uence on a patient’s resilience in the face of the 
stress of dealing with a chronic illness is their perceived level 
of social support. Overall the greater the level of perceived 
social support the less likely a patient will report symptoms 
of depression (McCathie et al 2002). In a study of 719 elderly 
individuals with a variety of chronic medical issues both 
strong social supports and effective personal coping strategies 
were associated with favorable effects in reducing levels of 
depression. In addition, for the 280 subjects in this study with 
lung disease (asthma, chronic bronchitis or emphysema), “dif-
fuse” relationships, those that were deﬁ  ned as less intimate, 
community-based relationships, were helpful in “buffering” 
the negative effects of the illness (Penninx et al 1998). Asso-
ciated with higher reports of depressive symptoms across International Journal of COPD 2007:2(4) 487
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all groups was patients’ receipt of “instrumental support” 
– tangible assistance with disease management. The suggested 
interpretation is that receiving high levels of instrumental 
support reinforces feelings of dependence and helplessness, 
countermanding feelings of self-efﬁ  cacy and mastery (Penning 
and Strain 1994). A single study focusing on determinants of 
depression in COPD patients found that the risk of depres-
sion was signiﬁ  cantly increased for subjects who lived alone, 
who had poor reversibility of FEV1 on spirometry and those 
who suffered severe functional impairment (van Manen et al 
2002).
These studies suggest that educating patients and caregiv-
ers in strategies that maximize independence, encouraging 
patients to develop and nurture their support systems and to 
participate in effective rehabilitation can help with both the 
physical and the psychosocial aspects of COPD. Certainly 
COPD can impose staggering losses on COPD patients and 
many of these same losses occur in other chronic illnesses, yet 
COPD patients demonstrate higher rates of depression. The 
explanations for this disparity include the early vulnerability 
posited by genetics studies and the longitudinal physiologic 
effects of chronic respiratory disease.
COPD effects on the CNS
Magnetic resonance imaging (MRI) is a non-radiological imag-
ing technique that offers detailed study of soft tissues. In the 
T2-weighted MRI scans CSF and other areas of acute anoxia 
or elevated ﬂ  uid content, such as that seen with edema, appear 
white. These sites of increased signal are termed hyperintensi-
ties (Yudofsky and Hales 1992). Multiple studies have noted 
an increased prevalence of these hyperintensities in subcorti-
cal areas in the brains of elderly subjects, collectively called 
subcortical hyperintensities (SH). The concentration of these 
subcortical lesions increases with advancing age but they are 
not universally associated with clinical pathology, appearing 
in imaging studies of both clinically compromised and healthy 
elderly subjects (Grafton et al 1991; Guttmann et al 1998). 
When present, SH are typically seen in the deep white matter, 
periventricular areas, the basal ganglia, the thalamus and the 
pons. These areas are particularly vulnerable to vascular insult 
because they are in identiﬁ  ed “watershed” or border zones of 
vascular supply. Considering all sites, the odds-ratio of ﬁ  nding 
SH increases by approximately 5% per additional year of age 
(Coffey et al 1992). While the lesions are seen in individuals 
without clinical disease, the prevalence and severity of SH 
do increase with cardiovascular risk factors as well as with a 
high burden of medical co-morbidity (Awad et al 1986; Brown 
et al 1992). The differential diagnosis for the lesions includes 
malignancies, infarcts and multiple sclerosis as well as less clin-
ically apparent, although still pernicious, conditions typically 
associated with aging. These include arteriosclerosis and the 
diminution of autoregulation of blood pressure and subsequent 
aberrations in blood ﬂ  ow (Campbell and Coffey 2001). In the 
absence of identiﬁ  ed cerebrovascular disease, other factors that 
have been associated with greater SH burden on MRI include 
clinically silent stroke, elevated systolic blood pressure and 
lower forced expiratory volume in 1 second (FEV1). When 
these factors are controlled for, smoking also emerges in posi-
tive association with SH (Longstreth et al 1996).
Several studies have found that the concentration of SH 
is also elevated in elderly patients with depression, with an 
even higher prevalence among the subset of patients whose 
depression developed after their 5th decade (Krishnan et al 
1988, 1993; Figiel et al 1991; Coffey et al 1993; Howard et al 
1993; Lesser et al 1996). In a meta-analysis a common odds 
ratio of 3.2 (95% CI 2.11–4.82) was found for the presence 
of SH in all patients with major depression (Videbech 1997). 
While not consistent across studies, there is some evidence 
that when compared to individuals who developed depression 
prior to 40 years of age, a higher concentration of SH is seen 
in older depressed subjects (Salloway et al 1996).
The concept of “vascular depression” was developed as 
a putative explanation for elders’ increased vulnerability to 
depression. Evidence supporting the concept includes literature 
showing that cerebrovascular disease often predates the onset 
of the depression; the increased prevalence of depression in 
individuals who also suffer from hypertension or coronary 
artery disease; and an increased ﬁ  nding of depressive symp-
toms in patients with vascular dementia when compared to 
those with non-vascular Alzheimer’s disease. Accumulating 
MRI evidence that shows a high concentration of SH in elderly, 
depressed patients, and the localization of those lesions in 
areas at increased risk for vascular compromise, strengthen 
the argument (Alexopoulos et al 1997a, 1997b). Contrasting 
studies in late onset depression have found a smaller associa-
tion with SH but a stronger one with decreased total brain 
volume, preserving the concept of structural damage albeit 
with a different manifestation (Rainer et al 2006).
Attempts have been made to identify a constellation of 
clinical factors that help with the identiﬁ  cation of late-onset 
depression. Late-onset depression has been found to be 
more refractory to treatment with antidepressants (Coffey 
et al 1988; Hickie et al 1995), associated with a greater 
degree of patient apathy (Krishnan et al 1995) and less often 
associated with a family history of depression (Fujikawa 
et al 1994; Krishnan et al 1997). Additionally, patients are International Journal of COPD 2007:2(4) 488
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less likely to achieve and sustain remission of their depressed 
symptoms (Fujikawa et al 1994; Taylor et al 2003). Relevant 
to clinical management, the concentration of SH has been 
associated with more problematic side effects in response 
to somatic treatments including delirium and parkinsonism 
with medications and ECT (Figiel, Coffey et al 1989; Figiel, 
Krishnan et al 1989; Fujikawa et al 1996).
There is strong evidence of an association between SH 
and late-onset depression, as well as between COPD and an 
increased severity of SH (van Dijk et al 2004). A portion of 
this increase may be accounted for by the subjects’ smoking 
history. Smoking has been shown to be cytotoxic to endothe-
lial cells and, as is discussed further below, this intravascular 
damage is a likely contributor to the observed SH (Blann and 
McCollum 1993). Smoking has also been shown to increase 
the risk for permanent brain injury following exposure to 
what might, in the absence of a smoking history, have been a 
transient ischemic insult (Wang et al 1997). The fundamental 
insult in ischemia is a failure to deliver sufﬁ  cient oxygen to 
the site of involvement and that insufﬁ  ciency can be caused 
by either hypoperfusion or hypoxemia. By the very nature 
of the disease process COPD is associated with chronic, if 
often subclinical, hypoxemia. The consequences of chronic 
hypoxemia include both impaired cognitive function and 
depression, although the evidence supporting the latter is less 
robust (El-Ad and Lavie 2005; Ozge et al 2006). In a compari-
son of cognitive function between healthy subjects, COPD 
patients and patients with Alzheimer’s disease (AD) with mild 
hypoxemia the AD patients had the worst performance, with 
the COPD patients showing signiﬁ  cant impairment relative 
to the normals (Kozora et al 1999). Imaging studies dem-
onstrate that worse hypoxemia in COPD is associated with 
decreased perfusion of anterior cortical and subcortical areas 
and decreased performance on cognitive testing relative to 
normals (Antonelli et al 2003). Most studies of hypoxemia 
and depression arise from the sleep apnea literature where 
one of the primary identiﬁ  ed sequelae of recurrent nocturnal 
hypoxemia is depressed mood (Aloia et al 2004).
It should be noted that depression itself has been identi-
ﬁ  ed as a risk factor for cerebrovascular insult, and so may 
contribute to the formation of lesions manifesting as SH. The 
severity of depressive symptoms is predictive of stroke after 
controlling for a host of variables including measured blood 
pressure (Simonsick et al 1995), smoking, body mass index, 
hypertension or diabetes (Everson et al 1998). A large, lon-
gitudinal study of 6095 stroke-free individuals followed for 
an average of 16 years found that after adjusting for multiple 
previously identiﬁ  ed risks for stroke (age, gender, ethnicity, 
systolic blood pressure, alcohol use, serum cholesterol level, 
diabetes and heart disease) being in the top third of measured 
depression levels increased the risk of stroke over the dura-
tion of the study period by 50%–106% when compared to 
subjects in the lowest third. The relative risk for stroke due 
to depression was roughly equivalent to a 40-point increase 
in systolic blood pressure (Jonas and Mussolino 2000).
Finally, there is growing evidence that depression and 
COPD impose similar microvascular and biochemical insults 
that would be expected to contribute to the accumulation of 
SH. Both depression and chronic respiratory disease have 
been associated with processes that jeopardize the microvas-
culature of the brain. In depression this has been evidenced by 
signiﬁ  cantly elevated biomarkers of oxidative damage. Lev-
els of 8-hydroxy-2'-deoxyguanosine were directly correlated 
with the severity of the depression and with the level of the 
resultant oxidative damage was correlated with the chronicity 
of the depression (Forlenza and Miller 2006). Oxidative stress 
has also been associated with biochemical alterations in the 
cell membrane and function of erythrocytes in patients with 
mental illness. These cell membrane aberrations are thought 
to interfere with effective transduction of neurotransmitter 
signaling (Ponizovsky et al 2003). In a treatment study 
depressed patients were noted to have deranged oxidant and 
antioxidant defense systems at baseline. After treatment with 
antidepressants depression measures improved and oxidative 
stress was reduced (Khanzode et al 2003).
In both COPD and depression there is evidence for 
increased platelet activation that may potentially lead to 
thrombotic insult to the microvasculature, the type of injury 
to which the narrow perforating arteries of the brain are 
particularly vulnerable. In COPD the synthesis of a marker 
of platelet activation was signiﬁ  cantly elevated and inversely 
related to arterial oxygen tension (Davi et al 1997). In a 
comparison of depressed patients and controls, the patients 
demonstrated increased platelet activation at baseline as well 
as increased platelet reactivity (Musselman et al 1996). In a 
small study of depressed patients treatment with the antide-
pressant sertraline diminished a pre-treatment elevation in 
platelet activation (Markovitz et al 2000).
Conclusion
COPD is a chronic, progressive disease and as such exerts an 
escalating burden over time. As the size of the elderly popula-
tion grows, the number of people suffering with this debilitating 
disease is certain to increase. In spite of the high prevalence of 
COPD, treatment continues to be primarily symptomatic and rates 
of functional impairment and mortality have not signiﬁ  cantly International Journal of COPD 2007:2(4) 489
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decreased in the past several decades. While our understanding 
of the disease continues to progress, our ability to halt, or better 
still reverse, the progression of the disease has not. Improved 
management of morbidity must then become a parallel goal and 
one of the areas with the greatest potential for improvement is 
the management of patients’ co-morbid depression. Depression 
in COPD is a heterogeneous entity with a potentially composite 
etiology including genetic predisposition, environmental losses 
and stressors, as well as direct damage to the brain mediated by 
the physiologic effects of chronic respiratory illness. As such, the 
relationships between depression, COPD and smoking are not 
linear but, rather, interconnected with each element inﬂ  uencing 
the others to different degrees in any given patient at any given 
time. Over the course of their lifetimes COPD patients may 
have experienced multiple exposures that increase their risk for 
the development of depression. The advantage to recognizing 
the inter-dependent relationship of these contributing factors is 
the corollary recognition that effective intervention in any one 
of them will have a cascading, positive impact on the others. 
Effectively targeting depression, or lost functionality or chronic 
hypoxemia will decrease morbidity in that dimension, and poten-
tially in the others as well. There is much research that remains 
to be done to delineate what the most effective interventions are, 
but they are progressing. As noted above, identiﬁ  cation of direct 
genetic inﬂ  uences opens the door for early intervention in juve-
nile vulnerability to nicotine addiction. Research into improved 
rehabilitation efforts, and a clariﬁ  cation of the best use and for-
mat of oxygen supplementation is ongoing with an eye to both 
decreased physiologic morbidity and increased functionality. At 
the same time patients are learning self-advocacy and developing 
support groups to share information and increase their sense of 
community. Lastly, we continue to search for the best ways to 
manage depression in patients with COPD. The likely answer will 
be a combination of psychopharmacology and psychotherapy, 
but in view of the often refractory nature of the depression there 
is also a role for electroconvulsive therapy in this population. 
This developing armamentarium can then be customized to the 
unique constellation of contributing factors active for a given 
patient at a given time.
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